ADC Therapeutics SA
ADCT
$3.43
-$0.05-1.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.85M | 23.06M | 16.43M | 18.84M | 23.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.85M | 23.06M | 16.43M | 18.84M | 23.03M |
| Cost of Revenue | 23.49M | 17.60M | 28.01M | 30.93M | 30.99M |
| Gross Profit | -2.64M | 5.46M | -11.58M | -12.09M | -7.96M |
| SG&A Expenses | 22.60M | 21.44M | 19.01M | 18.97M | 20.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.10M | 39.04M | 47.02M | 49.90M | 51.80M |
| Operating Income | -25.25M | -15.98M | -30.59M | -31.06M | -28.76M |
| Income Before Tax | -32.97M | -6.81M | -40.97M | -55.39M | -38.44M |
| Income Tax Expenses | -- | -404.00K | -- | 1.25M | 165.00K |
| Earnings from Continuing Operations | -32.97M | -6.41M | -40.97M | -56.65M | -38.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.97M | -6.41M | -40.97M | -56.65M | -38.60M |
| EBIT | -25.25M | -15.98M | -30.59M | -31.06M | -28.76M |
| EBITDA | -25.07M | -15.98M | -30.59M | -30.69M | -28.42M |
| EPS Basic | -0.26 | -0.04 | -0.30 | -0.50 | -0.36 |
| Normalized Basic EPS | -0.16 | -0.02 | -0.19 | -0.23 | -0.23 |
| EPS Diluted | -0.26 | -0.04 | -0.30 | -0.50 | -0.36 |
| Normalized Diluted EPS | -0.16 | -0.02 | -0.19 | -0.23 | -0.23 |
| Average Basic Shares Outstanding | 127.17M | 150.30M | 136.45M | 113.74M | 107.20M |
| Average Diluted Shares Outstanding | 127.17M | 150.30M | 136.45M | 113.74M | 107.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |